"Plus all of these sudden new indications give the impression this drug is too good to be true.... I am hoping it pans out but question my judgment in staying in..."

These additional indications aren't new. The company is following the lead of Pfizer, who owns a CCR5 antagonist too (maraviroc), that is vastly inferior to leronlimab, though, due to its toxicity.

The author of that SA article has no understanding of the science or HIV or CCR5 whatsoever - hell, he doesn't even know that leronlimab as a large-molecule monoclonal antibody can't be taken in pill form, he doesn't mention that we destroy competitors in MDR2+-MDR3 category regarding safety and efficacy and so on...

Basically, his message is: uuuuuh, don't know anything, too lazy looking up, have position, might sell it, uh or not, perhaps, don't believe in it anyway.

Ridiculous. "Out of Ignorance" is truly a fitting nickname. What a disingenious ***.

And looking at some of the comments at the SA articles/news and Yahoo: discounting the bashers, it is astonishing how many "investors" can't/don't actually read and interpret filings or press releases, yet (claim to) put their money into a clinical biotech. Jesus...